MA23258A1 - Nouvelle formule contenant une nouvelle forme physique d'un sel magnesium d'omeprazole, son procede de fabrication et son utilisation. - Google Patents

Nouvelle formule contenant une nouvelle forme physique d'un sel magnesium d'omeprazole, son procede de fabrication et son utilisation.

Info

Publication number
MA23258A1
MA23258A1 MA23568A MA23568A MA23258A1 MA 23258 A1 MA23258 A1 MA 23258A1 MA 23568 A MA23568 A MA 23568A MA 23568 A MA23568 A MA 23568A MA 23258 A1 MA23258 A1 MA 23258A1
Authority
MA
Morocco
Prior art keywords
omeprazole
magnesium salt
physical form
manufacturing
pct
Prior art date
Application number
MA23568A
Other languages
English (en)
Inventor
Ingmar Lovgren Kurt
Siv Bengisson Inga
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20390587&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA23258(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astra Ab filed Critical Astra Ab
Publication of MA23258A1 publication Critical patent/MA23258A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
MA23568A 1993-07-09 1994-07-07 Nouvelle formule contenant une nouvelle forme physique d'un sel magnesium d'omeprazole, son procede de fabrication et son utilisation. MA23258A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE19939302395A SE9302395D0 (sv) 1993-07-09 1993-07-09 New pharmaceutical formulation

Publications (1)

Publication Number Publication Date
MA23258A1 true MA23258A1 (fr) 1995-04-01

Family

ID=20390587

Family Applications (1)

Application Number Title Priority Date Filing Date
MA23568A MA23258A1 (fr) 1993-07-09 1994-07-07 Nouvelle formule contenant une nouvelle forme physique d'un sel magnesium d'omeprazole, son procede de fabrication et son utilisation.

Country Status (39)

Country Link
US (1) US5690960A (fr)
EP (1) EP0706378B1 (fr)
JP (1) JP3665334B2 (fr)
KR (1) KR100350203B1 (fr)
CN (1) CN1126946A (fr)
AT (1) ATE231719T1 (fr)
AU (1) AU681686B2 (fr)
BR (1) BR9406941A (fr)
CA (1) CA2166483C (fr)
CZ (1) CZ290323B6 (fr)
DE (1) DE69432076T2 (fr)
DK (1) DK0706378T3 (fr)
DZ (1) DZ1794A1 (fr)
EE (1) EE03148B1 (fr)
EG (1) EG22373A (fr)
ES (1) ES2191682T3 (fr)
FI (1) FI114008B (fr)
HR (1) HRP940386B1 (fr)
HU (1) HU226779B1 (fr)
IL (1) IL110189A0 (fr)
IS (1) IS2034B (fr)
LV (1) LV13140B (fr)
MA (1) MA23258A1 (fr)
MX (1) MX9405219A (fr)
MY (1) MY128809A (fr)
NO (1) NO315146B1 (fr)
NZ (1) NZ268694A (fr)
PL (1) PL175210B1 (fr)
RU (1) RU2138254C9 (fr)
SA (1) SA94150057B1 (fr)
SE (1) SE9302395D0 (fr)
SG (1) SG52365A1 (fr)
SI (1) SI0706378T1 (fr)
SK (1) SK281105B6 (fr)
TN (1) TNSN94078A1 (fr)
UA (1) UA43342C2 (fr)
WO (1) WO1995001783A1 (fr)
YU (1) YU49199B (fr)
ZA (1) ZA944934B (fr)

Families Citing this family (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9301830D0 (sv) * 1993-05-28 1993-05-28 Ab Astra New compounds
US6875872B1 (en) 1993-05-28 2005-04-05 Astrazeneca Compounds
SE9302395D0 (sv) * 1993-07-09 1993-07-09 Ab Astra New pharmaceutical formulation
FI970058L (fi) * 1994-07-08 1997-01-07 Astra Ab Uusi suun kautta annettava farmaseuttinen valmiste, joka sisältää omepratsolin magnesiumsuolaa
SE9402431D0 (sv) * 1994-07-08 1994-07-08 Astra Ab New tablet formulation
MX9600857A (es) * 1994-07-08 1997-06-28 Astra Ab Forma de dosificacion i en tabletas, con unidades multiples.
SE9500478D0 (sv) * 1995-02-09 1995-02-09 Astra Ab New pharmaceutical formulation and process
CR5278A (es) * 1995-03-24 1996-07-04 Lilly Co Eli Formulacion oral de 2-metil-tieno-benzodiacepina
US5945124A (en) * 1995-07-05 1999-08-31 Byk Gulden Chemische Fabrik Gmbh Oral pharmaceutical composition with delayed release of active ingredient for pantoprazole
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6645988B2 (en) 1996-01-04 2003-11-11 Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US6489346B1 (en) 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US6699885B2 (en) 1996-01-04 2004-03-02 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and methods of using same
SE512835C2 (sv) * 1996-01-08 2000-05-22 Astrazeneca Ab Doseringsform innehållande en mångfald enheter alla inneslutande syralabil H+K+ATPas-hämmare
SE508669C2 (sv) * 1996-04-26 1998-10-26 Astra Ab Nytt förfarande
US6623759B2 (en) 1996-06-28 2003-09-23 Astrazeneca Ab Stable drug form for oral administration with benzimidazole derivatives as active ingredient and process for the preparation thereof
DE19626045C2 (de) * 1996-06-28 1998-12-03 Klinge Co Chem Pharm Fab Stabile Arzneiform zur oralen Verabreichung, welche Omeprazol als aktiven Wirkstoff enthält, sowie Verfahren zur Herstellung derselben
CA2266448A1 (fr) * 1996-09-24 1998-04-02 Eli Lilly And Company Formulation de particules enrobees
TW385306B (en) * 1996-11-14 2000-03-21 Takeda Chemical Industries Ltd Method for producing crystals of benzimidazole derivatives
JP2001524131A (ja) 1997-05-09 2001-11-27 セイジ、ファーマスーティカルズ、インク 安定な経口医薬品剤形
SE9702000D0 (sv) * 1997-05-28 1997-05-28 Astra Ab New pharmaceutical formulation
SE510650C2 (sv) 1997-05-30 1999-06-14 Astra Ab Ny förening
US6747155B2 (en) 1997-05-30 2004-06-08 Astrazeneca Ab Process
SI9700186B (sl) * 1997-07-14 2006-10-31 Lek, Tovarna Farmacevtskih In Kemicnih Izdelkov, D.D. Nova farmacevtska oblika z nadzorovanim sproscanjem zdravilnih ucinkovin
US20050244497A1 (en) * 1997-11-05 2005-11-03 Wockhardt Limited Delayed delivery system for acid-sensitive drugs
US6096340A (en) * 1997-11-14 2000-08-01 Andrx Pharmaceuticals, Inc. Omeprazole formulation
US6174548B1 (en) 1998-08-28 2001-01-16 Andrx Pharmaceuticals, Inc. Omeprazole formulation
AU1671799A (en) * 1997-11-28 1999-06-16 Byk Gulden Lomberg Chemische Fabrik Gmbh Medicament preparation in the form of a tablet or pellet for acid-labile active substances
SE9704870D0 (sv) 1997-12-22 1997-12-22 Astra Ab New pharmaceutical formulation I
KR100627614B1 (ko) * 1998-04-20 2006-09-25 에자이 가부시키가이샤 안정화된 벤즈이미다졸계 화합물 함유 조성물로 이루어지는 의약제제
UA73092C2 (uk) * 1998-07-17 2005-06-15 Брістол-Майерс Сквібб Компані Таблетка з ентеросолюбільним покриттям і спосіб її приготування
US7094426B2 (en) * 1998-08-27 2006-08-22 Sage Pharmaceuticals, Inc. Stable oral pharmaceutical dosage forms
US6733778B1 (en) 1999-08-27 2004-05-11 Andrx Pharmaceuticals, Inc. Omeprazole formulation
SE9803772D0 (sv) * 1998-11-05 1998-11-05 Astra Ab Pharmaceutical formulation
IL142703A (en) * 1998-11-10 2006-04-10 Astrazeneca Ab Crystalline form of omeprazole
UA72748C2 (en) * 1998-11-10 2005-04-15 Astrazeneca Ab A novel crystalline form of omeprazole
EP1131316B1 (fr) * 1998-11-18 2004-07-21 AstraZeneca AB Procede chimique ameliore, et formulation pharmaceutique
US6365128B1 (en) * 1998-12-18 2002-04-02 Medical Defence Technologies, Llc Monitoring gastrointestinal function to guide care of high risk patients
EP1244430A4 (fr) * 1999-03-29 2004-01-14 Wyeth Corp Systeme d'enrobage
SE9902386D0 (sv) * 1999-06-22 1999-06-22 Astra Ab New formulation
IL130602A0 (en) * 1999-06-22 2000-06-01 Dexcel Ltd Stable benzimidazole formulation
US6245913B1 (en) 1999-06-30 2001-06-12 Wockhardt Europe Limited Synthetic procedure for 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methylthio]-IH-benzimidazole hydrochloride and its conversion to omeprazole
US6500459B1 (en) * 1999-07-21 2002-12-31 Harinderpal Chhabra Controlled onset and sustained release dosage forms and the preparation thereof
US6316020B1 (en) * 1999-08-26 2001-11-13 Robert R. Whittle Pharmaceutical formulations
HU229213B1 (en) 1999-10-20 2013-09-30 Eisai R & D Man Co Ltd Bunkyo Ku Method for stabilizing benzimidazole compounds
AU5248601A (en) * 2000-05-15 2001-11-26 Ranbaxy Laboratories Limited Novel amorphous form of omeprazole salts
ES2191521B1 (es) * 2000-11-22 2005-02-16 Laboratorios Belmac, S.A. Nueva formulacion galenica del omeprazol en forma de comprimidos, procedimiento para su preparacion y aplicaciones en medicina humana y en veterinaria.
US20030070584A1 (en) 2001-05-15 2003-04-17 Cynthia Gulian Dip coating compositions containing cellulose ethers
US8206741B2 (en) 2001-06-01 2012-06-26 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
DE60224056T2 (de) * 2001-08-27 2008-12-04 Kyowa Chemical Industry Co. Ltd., Takamatsu Antazide und laxative magnesiumoxid-tablette
US8309118B2 (en) 2001-09-28 2012-11-13 Mcneil-Ppc, Inc. Film forming compositions containing sucralose
EP1459737B1 (fr) * 2001-10-17 2012-09-26 Takeda Pharmaceutical Company Limited Granules contenant un agent chimique instable en milieu acide, en concentration elevee
CA2472103A1 (fr) * 2002-01-25 2003-08-07 Santarus, Inc. Administration par voie muqueuse d'inhibiteurs de la pompe a protons
AU2003209534A1 (en) * 2002-03-08 2003-09-22 Bakulesh Mafatlal Khamar The method of treating tuberculosis
US7429619B2 (en) 2002-08-02 2008-09-30 Mcneil Consumer Healthcare Polyacrylic film forming compositions
ES2299710T3 (es) * 2002-08-02 2008-06-01 Ratiopharm Gmbh Preparacion farmaceutica que contiene un compuesto de bencimidazol mezclado con celulosa microcristalina y un metodo para su preparacion.
MY148805A (en) 2002-10-16 2013-05-31 Takeda Pharmaceutical Controlled release preparation
RU2261021C2 (ru) * 2002-12-24 2005-09-27 Ромашев Николай Анатольевич Способ окрашивания твердой прессованной композиции
AU2003900096A0 (en) * 2003-01-10 2003-02-20 Nature Vet Orally deliverable pharmaceutical composition protein pump inhibitors
ITMI20030616A1 (it) * 2003-03-28 2004-09-29 Acme Drugs S R L Metodo per la preparazione di farmaci, alimenti, integratori alimentari, gastroprotetti e/o a rilascio controllato, prodotti dietetici, premiscele per mangim,i additivi per l'alimentazione zootecnica contenenti principi attivi sensibili all'ambiente
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
AR045068A1 (es) * 2003-07-23 2005-10-12 Univ Missouri Formulacion de liberacion inmediata de composiciones farmaceuticas
WO2005020954A2 (fr) * 2003-09-03 2005-03-10 Agi Therapeutics Limited Formulations inhibitrices de pompe a proton, et procedes d'elaboration et d'utilisation correspondantes
RU2257890C2 (ru) * 2003-10-06 2005-08-10 Марио Атилио Лос Способ получения устойчивых фармацевтических композиций в форме таблеток, содержащих омепразол, и фармацевтические композиции, полученные таким способом
US20050214388A1 (en) * 2004-02-18 2005-09-29 Gorham Thomas R Multivitamin formulations containing controlled-release magnesium
WO2005082888A1 (fr) * 2004-03-01 2005-09-09 Milen Merkez Ilac Endustrisi A.S. Procede de preparation d'un sel magnesique d'omeprazole
US8815916B2 (en) 2004-05-25 2014-08-26 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
CA2570916C (fr) 2004-06-16 2013-06-11 Tap Pharmaceutical Products, Inc. Forme posologique d'ipp a doses multiples
US20060024362A1 (en) * 2004-07-29 2006-02-02 Pawan Seth Composition comprising a benzimidazole and process for its manufacture
CN101111233A (zh) 2004-12-23 2008-01-23 兰贝克赛实验室有限公司 稳定的口服苯并咪唑组合物及其制备方法
EP1845982A2 (fr) * 2005-02-02 2007-10-24 Ranbaxy Laboratories Limited Compositions de benzimidazole orales stables preparees par un procede de stratification non aqueux
ES2675581T3 (es) 2005-02-25 2018-07-11 Takeda Pharmaceutical Company Limited Método para producir gránulos de un compuesto de bencimidazol recubiertos
JP2009511481A (ja) * 2005-10-06 2009-03-19 オースペックス・ファーマシューティカルズ・インコーポレイテッド 増強された治療特性を持つ、胃Ｈ＋，Ｋ＋−ＡＴＰａｓｅの重水素化阻害剤
EP2026768B1 (fr) * 2006-06-01 2018-02-28 Dexcel Pharma Technologies Ltd. Formulation pharmaceutique comprenant des unités multiples
WO2008014175A2 (fr) * 2006-07-28 2008-01-31 Dr. Reddy's Laboratories Ltd. Compositions pharmaceutiques granulaires
EP2068841B1 (fr) 2006-10-05 2018-09-26 Santarus, Inc. Nouvelles formulations pour une libération immédiate d'inhibiteurs de pompe à protons et procédés d'utilisation de ces formulations
MX2009004475A (es) 2006-10-27 2009-08-12 Univ Missouri Composiciones que comprenden agentes acido labiles que inhiben la bomba de protones, por lo menos otro agente farmaceuticamente activo y metodos de uso de las misma.
US20080194307A1 (en) * 2007-02-13 2008-08-14 Jeff Sanger Sports-based game of chance
WO2009113090A2 (fr) * 2008-01-17 2009-09-17 Alkem Laboratories Ltd. Procédé de préparation d’une formule orale d’un médicament à base de benzimidazole sensible à l’acide
CN101980700A (zh) 2008-02-20 2011-02-23 密苏里大学董事会 包含奥美拉唑和兰索拉唑以及缓冲剂的组合的组合物及其使用方法
US8911787B2 (en) 2008-02-26 2014-12-16 Ranbaxy Laboratories Limited Stable oral benzimidazole compositions and process of preparation thereof
ES2552723T3 (es) * 2008-05-06 2015-12-01 Dexcel Pharma Technologies Ltd. Formulación de bencimidazol estable
WO2009137648A1 (fr) * 2008-05-09 2009-11-12 Aptapharma, Inc. Pastilles multicouches inhibant la pompe à protons
EA201100313A1 (ru) 2008-09-09 2011-10-31 Астразенека Аб Способ доставки фармацевтической композиции пациенту, нуждающемуся в этом
UA112975C2 (uk) 2009-01-09 2016-11-25 Форвард Фарма А/С Фармацевтичний склад, що містить в матриці, яка піддається ерозії, один або більше ефірів фумарової кислоти
EA201290026A1 (ru) 2009-06-25 2012-07-30 Астразенека Аб Способ лечения пациента, имеющего риск развития язвы, связанной с приемом нестероидных противовоспалительных средств (nsaid)
EP2345408A3 (fr) 2010-01-08 2012-02-29 Dr. Reddy's Laboratories Ltd. Formulations de médicament labiles acides
EP2720605B1 (fr) 2011-06-14 2020-03-11 Gravitas Medical Inc. Appareil de guidage de soins médicaux sur la base d'une fonction gastrique détectée
CN104519888A (zh) 2011-12-28 2015-04-15 波曾公司 用于递送奥美拉唑和乙酰水杨酸的改良组合物和方法
CN103127026B (zh) * 2013-02-05 2017-02-15 悦康药业集团有限公司 一种奥美拉唑肠溶胶囊及其制备方法
CN103735526A (zh) * 2013-08-08 2014-04-23 上海海虹实业(集团)巢湖今辰药业有限公司 奥美拉唑镁肠溶片及其制作方法
CN103467453A (zh) * 2013-09-13 2013-12-25 上海海虹实业(集团)巢湖今辰药业有限公司 一种奥美拉唑镁原料药制备方法
WO2016174664A1 (fr) 2015-04-29 2016-11-03 Dexcel Pharma Technologies Ltd. Compositions à désintégration par voie orale
WO2017145146A1 (fr) 2016-02-25 2017-08-31 Dexcel Pharma Technologies Ltd. Compositions comprenant des inhibiteurs de la pompe à protons
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
CZ2017315A3 (cs) 2017-06-02 2018-12-12 Zentiva, K.S. Dávkovací jednotka s PPI (inhibitory protonové pumpy)
EP4098260A4 (fr) 2020-01-27 2023-07-12 Towa Pharmaceutical Co., Ltd. Préparation orale d'ésoméprazole et procédé de production associé
US11426353B2 (en) * 2020-06-24 2022-08-30 13400719 Canada Inc. Composite coating for an active agent
US20230263735A1 (en) * 2020-07-13 2023-08-24 Kirin Holdings Kabushiki Kaisha Film coated tablet
CN113350313B (zh) * 2021-06-23 2023-08-11 福建金山生物制药股份有限公司 一种艾司奥美拉唑镁延释制剂及其制备方法
EP4598528A1 (fr) 2022-10-04 2025-08-13 Arsenil Zabirnyk Inhibition de calcification de valve aortique

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7804231L (sv) * 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
SE8301182D0 (sv) * 1983-03-04 1983-03-04 Haessle Ab Novel compounds
GB2189698A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
JPH0768125B2 (ja) * 1988-05-18 1995-07-26 エーザイ株式会社 酸不安定化合物の内服用製剤
SE9302395D0 (sv) * 1993-07-09 1993-07-09 Ab Astra New pharmaceutical formulation
SE9302396D0 (sv) * 1993-07-09 1993-07-09 Ab Astra A novel compound form

Also Published As

Publication number Publication date
EP0706378A1 (fr) 1996-04-17
SK281105B6 (sk) 2000-12-11
DZ1794A1 (fr) 2002-02-17
US5690960A (en) 1997-11-25
NO960067L (no) 1996-01-05
MX9405219A (es) 1995-01-31
YU49199B (sh) 2004-09-03
TNSN94078A1 (fr) 1995-04-25
SG52365A1 (en) 1998-09-28
EG22373A (en) 2002-12-31
JP3665334B2 (ja) 2005-06-29
NO315146B1 (no) 2003-07-21
EP0706378B1 (fr) 2003-01-29
HK1008299A1 (en) 1999-05-07
EE03148B1 (et) 1999-02-15
AU681686B2 (en) 1997-09-04
UA43342C2 (uk) 2001-12-17
HU9503874D0 (en) 1996-02-28
FI114008B (fi) 2004-07-30
HRP940386A2 (en) 1997-02-28
FI960102L (fi) 1996-01-09
CA2166483C (fr) 1997-09-16
IS2034B (is) 2005-08-15
HRP940386B1 (en) 2003-10-31
NZ268694A (en) 1997-05-26
ES2191682T3 (es) 2003-09-16
SK2196A3 (en) 1997-04-09
HUT75306A (en) 1997-05-28
RU2138254C9 (ru) 2009-09-27
HU226779B1 (en) 2009-10-28
FI960102A0 (fi) 1996-01-09
PL175210B1 (pl) 1998-11-30
ZA944934B (en) 1995-02-20
PL312441A1 (en) 1996-04-29
ATE231719T1 (de) 2003-02-15
SI0706378T1 (en) 2003-06-30
LV13140B (en) 2004-08-20
YU43794A (sh) 1997-07-31
BR9406941A (pt) 1996-09-10
IL110189A0 (en) 1994-10-21
IS4187A (is) 1995-01-10
KR100350203B1 (ko) 2002-12-28
RU2138254C1 (ru) 1999-09-27
DE69432076T2 (de) 2003-10-16
DE69432076D1 (de) 2003-03-06
CZ7096A3 (en) 1996-06-12
DK0706378T3 (da) 2003-05-05
SA94150057B1 (ar) 2006-10-03
SE9302395D0 (sv) 1993-07-09
AU7198294A (en) 1995-02-06
JPH08512316A (ja) 1996-12-24
NO960067D0 (no) 1996-01-05
CZ290323B6 (cs) 2002-07-17
MY128809A (en) 2007-02-28
WO1995001783A1 (fr) 1995-01-19
CN1126946A (zh) 1996-07-17
CA2166483A1 (fr) 1995-01-19

Similar Documents

Publication Publication Date Title
MA23258A1 (fr) Nouvelle formule contenant une nouvelle forme physique d'un sel magnesium d'omeprazole, son procede de fabrication et son utilisation.
MA23744A1 (fr) Procede pour la preparation de sulfonamides, compositions pharmaceutiques les contenant et leur utilisation
GR3036642T3 (en) Novel benzoyl guanidines, their production and their use in medicaments
HUT77627A (hu) 2,2-Diklór-alkánkarbonsavak, eljárás előállításukra és ezeket tartalmazó, inzulinrezisztencia kezelésére alkalmazható gyógyszerkészítmények
DE69504509D1 (de) Thiazolidinderivate, ihre herstellung und medikamente, die sie enthalten
IL124966A (en) 1-indanyl-and 1-indanylidene-acetic acid derivatives
ES2006619A6 (es) Un metodo para preparar derivados de piridil-y pirimidil-piperazinas.
DE69400704D1 (de) N-acylpyrrolidine und arzneimittel zur behandlung oder prophylaxe von mit ckk und gastrin in zusammenhang stehenden krankheiten
NZ320522A (en) Piperazinylalkylthiopyrimidine derivatives, pharmaceutical compositions containing the same and a process for the preparation of the compounds
PL323305A1 (en) Applications of allyl amines
DE69516706D1 (de) Bis-2-aminopyridine, verfahren zu ihrer herstelung und ihre verwendung zur bekämpfung von parasitosen
ES2137665T3 (es) Nuevos derivados de piridina o piridazina, procedimientos para su preparacion, y medicamentos que contienen estos compuestos.
AU7000994A (en) Phosphosuccinic acid derivatives and their use as medicaments